Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DRUG TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EGULATORY
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING CANCER BURDEN WORLDWIDE
5.1.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
5.1.3 GROWING GERIATRIC POPULATION
5.1.4 RISING NUMBER OF PRODUCT APPROVAL
5.1.5 RISING EXPENDITURE ON HEALTHCARE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER SUPPORTIVE DRUGS
5.2.2 LACK OF EARLY DETECTION
5.3 OPPORTUNITIES
5.3.1 ACQUISITION AND AGREEMENT BY MAJOR PLAYERS
5.3.2 RISING PRODUCT LAUNCHES
5.3.3 GROWING R&D ACTIVITIES
5.4 CHALLENGES
5.4.1 STRINGENT REGULATION POLICY
5.4.2 PATENT EXPIRY OF DRUGS
6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS)
7.2.1 LONG ACTING FILGRASTIM
7.2.2 FILGRASTIM
7.2.3 LENOGRASTIM
7.3 ERYTHROPOIETIN STIMULATING AGENTS (ESA’S)
7.3.1 EPO-Α/Β
7.3.2 DPO
7.3.3 CERA
7.3.4 EPO-Κ
7.4 OPIOID ANALGESICS
7.4.1 FENTANYL
7.4.2 METHADONE
7.4.3 TRAMADOL
7.4.4 OTHERS
7.5 MONOCLONAL ANTIBODIES
7.6 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
7.6.1 OTC NSAIDS
7.6.1.1 ASPIRIN
7.6.1.2 IBUPROFEN
7.6.1.3 NAPROXEN SODIUM
7.6.2 PRESCRIPTION NSAIDS
7.6.2.1 CELECOXIB
7.6.2.2 DICLOFENAC
7.6.2.3 INDOMETHACIN
7.6.2.4 KETOROLAC
7.6.2.5 MELOXICAM
7.6.2.6 NABUMETONE
7.6.2.7 NAPROXEN
7.6.2.8 OXAPROZIN
7.6.2.9 PIROXICAM
7.6.2.10 SULINDAC
7.6.2.11 OTHERS
7.7 BISPHOSPHONATES
7.7.1 ZOLEDRONIC ACID OR ZOLEDRONATE
7.7.2 DISODIUM PAMIDRONATE
7.7.3 IBANDRONIC ACID OR IBANDRONATE
7.7.4 SODIUM CLODRONATE
7.8 ANTI-EMETICS
7.8.1 APREPITANT
7.8.2 DEXAMETHASONE
7.8.3 DOLASETRON
7.8.4 GRANISETRON
7.8.5 ONDANSETRON
7.8.6 PALONOSETRON
7.8.7 PROCHLORPERAZINE
7.8.8 ROLAPITANT
7.8.9 OTHERS
7.9 ANTIHISTAMINES
7.9.1 HYDROXYZINE
7.9.2 DIPHENHYDRAMINE
7.9.3 OTHERS
7.1 OTHERS
8 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE
8.1 OVERVIEW
8.2 BRANDED
8.2.1 NEULASTA
8.2.2 ARANESP
8.2.3 PROLIA
8.2.4 XGEVA
8.2.5 EPOGEN
8.2.6 EPREX
8.2.7 NEUPOGEN
8.2.8 OTHERS
8.3 GENERICS
9 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 LUNG CANCER
9.3 BREAST CANCER
9.4 PROSTATE CANCER
9.5 LIVER CANCER
9.6 BLADDER CANCER
9.7 LEUKAEMIA
9.8 MELANOMA
9.9 OVARIAN CANCER
9.1 OTHER CANCERS
10 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.2.1 ACUTE CARE HOSPITALS
10.2.2 LONG-TERM CARE HOSPITALS
10.2.3 NURSING FACILITIES
10.3 CLINICS
10.4 HOSPITALS & ACADEMIC INSTITUTIONS
10.5 OTHERS
11 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACIES
11.3 RETAIL PHARMACIES
11.4 COMPOUNDING PHARMACIES
12 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY GEOGRAPHY
12.1 MIDDLE EAST & AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 UAE
12.1.4 ISRAEL
12.1.5 EGYPT
12.1.6 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
14 SWOT
15 COMPANY PROFILES
15.1 AMGEN INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 PFIZER INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOVARTIS AG
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 ACACIA PHARMA GROUP PLC
15.5.1 COMPANY SNAPSHOT
15.5.2 PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ACROTECH BIOPHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 APR
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 BAXTER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 HELSINN HEALTHCARE SA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 HERON THERAPEUTICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 KYOWA KIRIN CO., LTD.
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 MYLAN N.V.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENTS
15.16 OXFORD PHARMASCIENCE LTD
15.16.1 COMPANY SNAPSHOT
15.16.2 TECHNOLOGY PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SPECTRUM PHARMACEUTICALS, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 TERSERA THERAPEUTICS LLC
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 MORTALITY DUE TO CANCER, AGES 85+, IN THE U.S.
TABLE 3 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2020-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE 2020-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENERICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2020-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LUNG CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA BREAST CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA LIVER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA BLADDER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA LEUKAEMIA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA MELANOMA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OVARIAN CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHER CANCERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CLINICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HOSPITALS & ACADEMIC INSTITUTIONS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA COMPOUNDING PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 64 SOUTH AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 SOUTH AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 80 SAUDI ARABIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 96 UAE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 97 UAE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 UAE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 UAE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 UAE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 102 UAE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 103 UAE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 104 UAE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 105 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 UAE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 108 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 109 UAE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 112 ISRAEL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 128 EGYPT GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 129 EGYPT OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 130 EGYPT ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 131 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 132 EGYPT OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 133 EGYPT PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 134 EGYPT BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 136 EGYPT ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 137 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 EGYPT BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 139 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 140 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 141 EGYPT HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 143 REST OF MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 10 GROWING CANCER BUREN WORLDWIDE IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 14 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES (WORLD) IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 15 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020
FIGURE 16 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020
FIGURE 24 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020
FIGURE 28 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 32 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020)S
FIGURE 36 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020)
FIGURE 37 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 38 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028)
FIGURE 40 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%)
